Rhythm Pharma Q2 revenue $48.5M (+29% seq), net loss $(48.0M); advances setmelanotide filings for AHO

RHYTHM PHARMACEUTICALS, INC.

2025-Q2 EPS reported -$1.56 revenue$81,206,000

Q2 net product revenue $48.5M, up 29% sequentially from Q1 2025; US revenue $32.0M (66% of total), up 31%.
Net loss $(48.0)M ($(0.75)/share) vs $(33.6)M ($(0.55)/share) in Q2 2024.
Cash $291M at June 30; added ~$189.2M from July stock offering; paid $40M to LG Chem for bivamelagon.
Phase 3 TRANSCEND: setmelanotide achieved placebo-adjusted BMI reduction of -19.8% in acquired hypothalamic obesity (AHO).
Regulatory submissions for setmelanotide in AHO to FDA and EMA on track for Q3 2025; FY 2025 Non-GAAP OpEx guidance $285-315M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.